Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amrion magnesium, boron osteoporosis claims unapproved health, drug claims -- FDA.

This article was originally published in The Tan Sheet

Executive Summary

AMRION MAGNESIUM, BORON OSTEOPOROSIS CLAIMS ARE DRUG CLAIMS, FDA tells the company in a Dec. 1 "courtesy letter" recently made available by the agency. Amrion had filed structure/function claims regarding a link between various substances and osteoporosis for its HealthSmart Daily Essentials, HealthSmart Calcium Carbonate and HealthSmart Calcium & Magnesium Complex. "These statements are not statements of nutritional support subject to section 403(r)(6) of the [Food, Drug & Cosmetic Act], but are health claims subject" to another section of the act, FDA stated. Supplement manufacturers are only permitted to make health claims for calcium and osteoporosis. Amrion plans to make all of the modifications requested by FDA.

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088197

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel